2269 N Overzicht aandelen An investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. Meer informatie
Beloningen Risicoanalyse Alle risicocontroles bekijken {"enabled":false,"variant":{"name":"disabled","enabled":false},"ready":false,"error":null}
Leg je gedachten, links en bedrijfsverhaal vast
WuXi Biologics (Cayman) Inc. Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor WuXi Biologics (Cayman) Historische aandelenkoersen Huidige aandelenkoers HK$62.53 52 Week Hoogtepunt HK$62.53 52 Week Laag HK$62.53 Bèta 0.66 1 maand verandering 0% 3 maanden verandering n/a 1 Jaar Verandering n/a 3 jaar verandering -74.45% 5 jaar verandering n/a Verandering sinds IPO -73.63%
Recent nieuws en updates
WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718). Oct 25
WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom Oct 05
WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing Aug 30
WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024 Jul 25
Wuxi Biologics (Cayman) Inc. Announces Retirement of Weichang Zhou as Chief Technology Officer and President of Global Biologics Development and Operations and Re-Designates as Non-Executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer Apr 03
WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024 Mar 27 Meer updates bekijken
WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718). Oct 25
WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom Oct 05
WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing Aug 30
WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024 Jul 25
Wuxi Biologics (Cayman) Inc. Announces Retirement of Weichang Zhou as Chief Technology Officer and President of Global Biologics Development and Operations and Re-Designates as Non-Executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer Apr 03
WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024 Mar 27
WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P Global 1200 Mar 19 WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700
WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024 Feb 15
WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland Feb 01
WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect Jan 25
WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™ Jan 17
WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024 Jan 16
Less than half of directors are independent Dec 22
WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023. Dec 08
Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale Nov 22
WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality Oct 17
Wuxi Biologics (Cayman) Inc. Announces Executive Changes Aug 17
WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023 Jul 26 WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023 May 25
WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee May 18
WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes May 09
Investor sentiment deteriorates as stock falls 26% Feb 23
Less than half of directors are independent Feb 23 WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023
Less than half of directors are independent Jan 31
WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company Nov 26
Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee Nov 24
WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022. Oct 01
First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021) Sep 24
WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA Sep 20
Investor sentiment deteriorated over the past week Sep 19
Less than half of directors are independent Sep 19
First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021) Aug 18
Less than half of directors are independent Aug 18
WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee Aug 18 WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022
Less than half of directors are independent Jul 18
CEO & Executive Director recently sold Mex$45m worth of stock Jun 17
Investor sentiment improved over the past week Jun 13
Less than half of directors are independent May 30
Less than half of directors are independent Feb 12 Wuxi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Ended December 31, 2021
WuXi Biologics Announces Completion of GMP Production At 24,000L Line of Its Drug Substance Facility MFG5 Nov 24
CEO & Executive Director recently bought Mex$102m worth of stock Nov 07
Less than half of directors are independent Oct 26
WuXi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021 Jul 15
CEO & Executive Director recently sold Mex$88m worth of stock Jun 17 WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.
Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.27 in FY 2019) May 01
Insider recently bought Mex$9.2m worth of stock Mar 31
Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.27 in FY 2019) Mar 25
WuXi Biologics (Cayman) Inc. (SEHK:2269) agreed to acquire a 90% stake in CMAB Biopharma Inc. from CBC Group. Mar 19
WuXi Biologics (Cayman) Inc. (SEHK:2269) entered into an equity agreement to acquire Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd. Mar 17
Exelixis, Inc. Enters into License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline Mar 10
Wuxi Biologics (Cayman) Inc. Receives Remote Pre-Approval Inspection by European Medicines Agency on MFG4 Facility Mar 04
WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021 Feb 27
Antengene Corporation Limited Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage Feb 01
Executive VP recently sold Mex$275m worth of stock Jan 28
Oxford BioTherapeutics Ltd Designates Second Bispecific Antibody Program Leveraging Wuxi Biologics’ Wuxibody® Platform Jan 21
Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform Jan 20
WuXi Biologics Receives GMP Certification from Brazil's ANVISA Dec 29 Rendement voor aandeelhouders 2269 N MX Life Sciences MX Markt 7D 0% 0% 0% 1Y n/a 0% 0%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe 2269 N presteerde ten opzichte van de MX Life Sciences.
Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe 2269 N presteerde ten opzichte van de MX markt.
Prijsvolatiliteit Is 2269 N's price volatile compared to industry and market? 2269 N volatility 2269 N Average Weekly Movement n/a Life Sciences Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
Stabiele aandelenkoers: 2269 N heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de MX markt.
Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 2269 N in het afgelopen jaar te bepalen.
Over het bedrijf Meer tonen WuXi Biologics (Cayman) Inc. Samenvatting Hoe verhouden de winst en inkomsten van WuXi Biologics (Cayman) zich tot de beurswaarde? 2269 N fundamentele statistieken Marktkapitalisatie Mex$132.67b Inkomsten(TTM ) Mex$9.71b Inkomsten(TTM ) Mex$38.71b
13.7x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) 2269 N resultatenrekening (TTM ) Inkomsten CN¥16.55b Kosten van inkomsten CN¥9.68b Brutowinst CN¥6.87b Overige uitgaven CN¥2.72b Inkomsten CN¥4.15b
Laatst gerapporteerde inkomsten
Jun 30, 2023
Volgende inkomensdatum
Mar 26, 2024
Winst per aandeel (EPS) 0.99 Brutomarge 41.51% Nettowinstmarge 25.08% Schuld/Eigen Vermogen Verhouding 7.7%
Hoe presteerde 2269 N op de lange termijn?
Bekijk historische prestaties en vergelijking
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2024/03/18 08:11 Aandelenkoers aan het einde van de dag 2023/12/20 00:00 Inkomsten 2023/06/30 Jaarlijkse inkomsten 2022/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie .
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github .
Bronnen van analisten WuXi Biologics (Cayman) Inc. wordt gevolgd door 56 analisten. 32 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Wai Chak Yuen BOCI Research Ltd. Linda Lu BOCI Research Ltd. Bo Li BofA Global Research
Toon 53 meer analisten 